What is the price target for TVRD stock?
14 analysts have analysed TVRD and the average price target is 8.5 USD. This implies a price increase of 172.43% is expected in the next year compared to the current price of 3.12.
TVARDI THERAPEUTICS INC (TVRD) Forecast, Price Target & Analyst Ratings
NASDAQ:TVRD • US1407553072
Current stock price
3.12 USD
-0.03 (-0.95%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TVARDI THERAPEUTICS INC (TVRD).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 19, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.76
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.50
Upside
+ 172.43%
From current price of $3.12 to mean target of $8.50, Based on 14 analyst forecasts
Low
$3.03
Median
$8.16
High
$15.75
Price Target Revisions
1 Month
-43.91%
3 Months
-43.91%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for TVRD. The average price target is 8.5 USD. This implies a price increase of 172.43% is expected in the next year compared to the current price of 3.12.
The average price target has been revised downward by 43.91% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
78.57%
TVRD was analyzed by 14 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about TVRD.
In the previous month the buy percentage consensus was at a similar level.
TVRD was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-20 | Barclays | Downgrade | Equal-Weight -> Underweight |
| 2026-04-01 | BTIG | Reiterate | Buy -> Buy |
| 2026-04-01 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-04-01 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-10-14 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2025-10-13 | BTIG | Maintains | Buy -> Buy |
| 2025-10-13 | Barclays | Initiate | Overweight |
| 2025-07-14 | Raymond James | Initiate | Outperform |
| 2025-07-11 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-06-12 | Piper Sandler | Initiate | Overweight |
| 2025-05-21 | Oppenheimer | Initiate | Outperform |
| 2025-04-28 | Jones Trading | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 19, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.76
- Revenue Estimate
- Revenue Q2Q
- -100.00%
- EPS Q2Q
- 76.42%
- Number of Analysts
- 9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
TVRD is expected to report earnings on 5/19/2026. The consensus EPS estimate for the next earnings is -0.76 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 41.9M 82.17% | 20.968M -49.96% | 7.137M -65.96% | 331.5K -95.36% | -100.00% | 4.898M | 22.143M 352.08% | 28.307M 27.84% | 48.598M 71.68% | 71.452M 47.03% | |||
| EBITDA YoY % growth | -87.25M 1.80% | -121.236M -38.95% | -52.723M 56.51% | -28.56M 45.83% | -39.78M -39.29% | -49.98M -25.64% | -56.1M -12.24% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -87.5M 1.80% | -121.495M -38.85% | -52.818M 56.53% | -26.185M 50.42% | -27.74M -5.94% | -40.524M -46.08% | -48.726M -20.24% | -58.458M -19.97% | -39.587M 32.28% | -43.329M -9.45% | -17.615M 59.35% | 1.092M 106.20% | |
| Operating Margin | -208.83% | -579.43% | -740.06% | -7,898.85% | N/A | N/A | N/A | -1,193.50% | -178.78% | -153.07% | -36.25% | 1.53% | |
| EPS YoY % growth | -57.24 8.09% | -78.48 -37.11% | N/A 98.33% | -2.50 -327.04% | -2.50 55.29% | -2.78 -11.17% | -3.01 -8.17% | -1.91 36.40% | -1.06 44.61% | -1.30 -22.35% | -0.76 41.47% | -0.38 49.32% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.76 76.42% | -0.71 29.04% | -0.62 -4.47% | -0.46 40.41% | -0.56 26.55% | -0.58 18.07% | -0.58 6.23% | -0.60 -29.47% |
| Revenue Q2Q % growth | -100.00% | |||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.173M -200.63% | -7.124M 19.68% | -7.144M -20.31% | -7.867M -29.48% | -8.07M -12.51% | -8.49M -19.18% | -8.943M -25.18% | -9.433M -19.91% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
13.50%
EPS Next 5 Year
12.61%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
131.71%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
12.96%
EBIT Next 5 Year
8.24%
TVARDI THERAPEUTICS INC / TVRD Forecast FAQ
When does TVARDI THERAPEUTICS INC (TVRD) report earnings?
TVARDI THERAPEUTICS INC (TVRD) will report earnings on 2026-05-19.
Can you provide the consensus estimates for TVARDI THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of TVARDI THERAPEUTICS INC (TVRD) is -0.76 USD and the consensus revenue estimate is 0 USD.
What is the expected long term growth rate for TVRD stock?
The expected long term growth rate for TVARDI THERAPEUTICS INC (TVRD) is -25.99%.